About 9,300 men in the U.S. each year are affected by HPV-caused cancers, among them Oropharyngeal Cancer
that occurs in the middle part of the throat behind the mouth and can
develop around the tonsils and the back of the tongue. That number is
expected to grow dramatically in the coming years.
The study, released online Monday in
CANCER,
a peer-reviewed journal of the American Cancer Society, indicates that
vaccinating 12-year-old boys against HPV is a cost-effective strategy
for preventing throat cancer.
Researchers applied a statistical model to 192,940 Canadian boys who
were 12 years old in 2012, and found that vaccination could save $6
million to $22 million, depending on the cost of the vaccine, its
effectiveness, the cost of cancer treatment and the survival rate of
patients who get cancer.
Data from the U.S. Centers for Disease Control and Prevention show vaccination
rates
for males climbed from 20.8 percent in 2012 to 34.6 percent in 2013.
Sui says that if more boys were vaccinated, then the vaccine would
prevent throat cancer as effectively as it prevents cervical cancer.
For women, the vaccines Gardasil and Cervarix protect against 70
percent of cervical cancers and 90 percent of genital warts cases. They
work in the body for at least a decade without becoming less effective
and
have not been associated with any long-term health problems. Gardasil is the vaccine typically given to men.
No comments:
Post a Comment